CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet ...
Clearside Biomedical Showcases Suprachoroidal Injection Platform for Retinal Diseases at CTS Meeting
Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...
ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical (CLSD), Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
On Wednesday, Clearside Biomedical, Inc. (NASDAQ:CLSD) announced that the ODYSSEY Phase 2b trial of CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration (wet AMD) ...
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space (SCS ...
The New Times on MSN
Six-month HIV prevention injection set for rollout by year-end
The government plans to introduce lenacapavir, a long-acting injectable drug for HIV prevention, in the last quarter of the ...
The global diabetes injection pens market is projected to grow at a CAGR of approximately 7% through 2028. Market expansion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback